AI Article Synopsis

  • Long-term follow-up studies on patients with extrahepatic portal venous obstruction (EHPVO) post-endoscopic sclerotherapy (EST) for esophageal varices are scarce.
  • A study tracked 198 patients for around 20 years, revealing that 17.2% experienced rebleeding, mostly due to recurrent varices.
  • Despite some recurrence, EST is deemed effective, with notable stability in patient condition after the first decade post-treatment.

Article Abstract

Background: Long-term follow-up studies of patients with extrahepatic portal venous obstruction (EHPVO) after eradication of esophageal varices using endoscopic sclerotherapy (EST) are limited.

Methods: Between 1985 and 1994, 223 patients with bleeding esophageal varices due to EHPVO underwent variceal eradication using EST. Regular annual clinical and endoscopic follow-up data were available for 198 of these patients for a mean period of 19.8 (range: 14-23) years. These data were analyzed retrospectively.

Results: Of the 198 patients, 34 (17.2%) had rebleeding after variceal eradication. The mean duration from variceal eradication to recurrence of bleeding was 5.4 years. The causes of rebleeding were: recurrent esophageal varices in 21 patients, fundal varices in eight, portal gastropathy in three, and ectopic varices in two patients. Esophageal varices reappeared in 39 (19.7%) patients. Fundal varices appeared in 19 (9.5%) patients during follow-up.

Conclusions: EST is an effective treatment modality for bleeding esophageal varices due to EHPVO. During a follow-up of nearly 20 years after variceal eradication, only about one-sixth of the patients had recurrence of gastrointestinal bleeding. Bleeding was unusual after 10 years had passed since initial variceal eradication.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12664-009-0086-0DOI Listing

Publication Analysis

Top Keywords

variceal eradication
24
esophageal varices
20
bleeding esophageal
12
patients
10
patients extrahepatic
8
extrahepatic portal
8
portal venous
8
venous obstruction
8
varices
8
varices ehpvo
8

Similar Publications

Esophageal variceal (EV) diameter is a critical, independent risk factor for hemorrhage, and plays a key role in guiding choices of endoscopic treatment techniques. We developed a novel tool, the virtual ruler (VR), which offers increased precision and expediency in EV diameter (EVD) measurements. This study investigates the clinical value of VR for assessing EVD during the endoscopic treatment of cirrhotic EVs.

View Article and Find Full Text PDF

Introduction: The safety of continuing anticoagulation therapy during endoscopic variceal ligation (EVL) remains controversial. We performed a systematic review and meta-analysis to evaluate the safety of anticoagulation therapy in EVL.

Methods: We systematically searched four electronic databases from their inception until 1 June 2024, for studies that evaluated anticoagulation use and risk of rebleeding among patients undergoing EVL.

View Article and Find Full Text PDF

Mutations in doublecortin domain-containing protein 2 (DCDC2) lead to neonatal sclerosing cholangitis (NSC), and portal hypertension (PHTN). The objective of the study was to systematically evaluate PHTN, variceal bleeding, and outcomes of patients with DCDC2-related NSC. The study included children with homozygous or compound heterozygous variants in DCDC2.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the effectiveness of two techniques—percutaneous transhepatic obliteration with initial afferent vein embolization (PTO-A) and initial efferent vein embolization (PTO-E)—for treating gastric varices (GVs).
  • 26 patients with type 1 or type 2 gastric varices were treated, with positive outcomes seen in both methods; however, PTO-E demonstrated a significantly higher complete eradication rate (100% vs. 33.3%).
  • Patients who underwent PTO-E also experienced a longer median recurrence-free period (75.1 months) compared to those who had PTO-A (8.7 months), although overall survival rates were similar for both groups.
View Article and Find Full Text PDF

Portal vein stenting blocked the inflow tract and completely resolved bile duct varices, formed by cavernous transformation of the portal vein.

Clin J Gastroenterol

December 2024

Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, Kumamoto-shi, 860-0811, Japan.

There is no established treatment for bleeding bile duct varices (BDVs). We report the first case of portal vein (PV) stenting completely eradicating bleeding BDVs. A 70-year-old male with malignant lymphoma developed BDVs due to PV obstruction, which had caused compression and stricture of the distal bile duct.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!